BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2014 10:47:00 AM | Browse: 1117 | Download: 1234
Publication Name World Journal of Gastroenterology
Manuscript ID 9559
Country/Territory China
Received
2014-02-17 16:43
Peer-Review Started
2014-02-17 20:02
To Make the First Decision
2014-03-27 21:15
Return for Revision
2014-03-31 10:06
Revised
2014-04-28 00:00
Second Decision
2014-05-26 21:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-26 21:49
Articles in Press
2014-05-26 22:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-06-18 22:35
Typeset the Manuscript
2014-11-28 16:54
Publish the Manuscript Online
2014-12-02 10:46
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research & Experimental
Manuscript Type Autobiography
Article Title Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats
Manuscript Source Unsolicited Manuscript
All Author List Qing-Hong Du, Lin Han, Jun-Jie Jiang, Ya Xu, Wei-Hong Li, Peng-Tao Li, Xin-Yue Wang and Xu Jia
Funding Agency and Grant Number
Funding Agency Grant Number
National Key New Drug Creation Project of China 2009ZX09102
National Natural Science Foundation of China 81273885
Corresponding Author Wei-Hong Li, MD, School of Fundamental Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Beijing 100029, China. liweihong.403@163.com
Key Words Glytan; Portal hypertension; Hemodynamics; Mesentery; Endothelin-1; Receptor; Sensitivity
Core Tip The traditional Chinese medicine Glytan is composed of salvianolic acid B and diammonium glycyrrhizinate. Previous studies have shown that Glytan is a new preparation for portal hypertension. The present study indicated that decreases in portal pressure and portal territory blood flow observed after Glytan treatment in portal hypertensive rats were related to increased mesenteric endothelin-1 content and reduced endothelin B receptor, endothelial NO synthase, G-protein-coupled receptor kinase 2, and ?-arrestin 2 expression, which may promote mesenteric vasoconstriction and increase receptor sensitivity to vasoconstrictors. These results suggest the therapeutic potential of Glytan in portal hypertension induced by liver cirrhosis.
Publish Date 2014-12-02 10:46
Citation Du QH, Han L, Jiang JJ, Xu Y, Li WH, Li PT, Wang XY, Jia X. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats. World J Gastroenterol 2014; 20(44): 16674-16682
URL http://www.wjgnet.com/1007-9327/full/v20/i44/16674.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i44.16674
Full Article (PDF) WJG-20-16674.pdf
Full Article (Word) WJG-20-16674.doc
Manuscript File 9559-Review.doc
Answering Reviewers 9559-Answering reviewers.pdf
Copyright License Agreement 9559-Copyright assignment.pdf
Peer-review Report 9559-Peer review.pdf
Scientific Misconduct Check 9559-CrossCheck.jpg
Scientific Editor Work List 9559-Scientific editor work list.pdf